GlassScriptPhysician profile
Tracy Ann Lutche
NPI 1609332485
$2,039.38
in general payments reported to CMS, 2019-2025
8 companies · $562 in 2025
The $562 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.06 · 2023: $817 · 2024: $641 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.33 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $733.93 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $605.40 | 2022-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $291.26 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $169.39 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $147.55 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $34.24 | 2023-2024 | Uzedy, Austedo Xr |
| Abbvie INC. | $33.38 | 2024 | |
| Indivior INC. | $24.23 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Lutche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.